| Literature DB >> 23515199 |
Z Paul Lorenc1, Jeffrey M Kenkel, Steven Fagien, Haideh Hirmand, Mark S Nestor, Anthony P Sclafani, Jonathan M Sykes, Heidi A Waldorf.
Abstract
OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.Mesh：
Substances：
Year: 2013 PMID： 23515199 DOI： 10.1177/1090820X12474629
Source DB: PubMed Journal: Aesthet Surg J ISSN： 1090-820X Impact factor: 4.283